|
1
|
A gene-expression signature as a predictor of survival in breast cancer.
|
N Engl J Med
|
2002
|
58.15
|
|
2
|
Concordance among gene-expression-based predictors for breast cancer.
|
N Engl J Med
|
2006
|
13.50
|
|
3
|
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.
|
Proc Natl Acad Sci U S A
|
2005
|
10.85
|
|
4
|
Gene expression profiles of primary breast tumors maintained in distant metastases.
|
Proc Natl Acad Sci U S A
|
2003
|
4.47
|
|
5
|
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
|
Lancet Oncol
|
2007
|
3.32
|
|
6
|
Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method.
|
Cancer Res
|
2003
|
3.02
|
|
7
|
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
|
Breast Cancer Res Treat
|
2011
|
2.73
|
|
8
|
Modeling precision treatment of breast cancer.
|
Genome Biol
|
2013
|
2.42
|
|
9
|
Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.
|
Lancet Oncol
|
2009
|
2.17
|
|
10
|
A protocol for building and evaluating predictors of disease state based on microarray data.
|
Bioinformatics
|
2005
|
2.08
|
|
11
|
Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation.
|
J Natl Cancer Inst
|
2003
|
2.02
|
|
12
|
Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations.
|
Cancer Res
|
2005
|
1.70
|
|
13
|
Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.
|
Cancer Res
|
2002
|
1.64
|
|
14
|
A comparison of univariate and multivariate gene selection techniques for classification of cancer datasets.
|
BMC Bioinformatics
|
2006
|
1.57
|
|
15
|
Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment.
|
Blood
|
2004
|
1.56
|
|
16
|
Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma.
|
J Clin Oncol
|
2007
|
1.50
|
|
17
|
Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?
|
Genet Med
|
2005
|
1.27
|
|
18
|
The role of genetic breast cancer susceptibility variants as prognostic factors.
|
Hum Mol Genet
|
2012
|
1.23
|
|
19
|
Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers.
|
Breast Cancer Res Treat
|
2004
|
1.19
|
|
20
|
Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary?
|
Clin Cancer Res
|
2005
|
1.17
|
|
21
|
The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients.
|
Breast Cancer Res
|
2011
|
1.07
|
|
22
|
Implementation of a novel microarray-based diagnostic test for cancer of unknown primary.
|
Int J Cancer
|
2009
|
1.03
|
|
23
|
Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations.
|
J Med Genet
|
2013
|
1.01
|
|
24
|
An "elite hacker": breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity.
|
Cell Adh Migr
|
2012
|
0.99
|
|
25
|
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.
|
Breast Cancer Res Treat
|
2012
|
0.96
|
|
26
|
The insulin-like growth factor system in cancer prevention: potential of dietary intervention strategies.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.94
|
|
27
|
Hard-wired genotype in metastatic breast cancer.
|
Cell Cycle
|
2004
|
0.91
|
|
28
|
A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences.
|
Mol Oncol
|
2013
|
0.90
|
|
29
|
A prognostic gene expression profile that predicts circulating tumor cell presence in breast cancer patients.
|
PLoS One
|
2012
|
0.89
|
|
30
|
A clinicopathologic analysis of peritoneal metastases of colorectal and appendiceal origin.
|
Ann Surg Oncol
|
2010
|
0.88
|
|
31
|
Two TP53 germline mutations in a classical Li-Fraumeni syndrome family.
|
Fam Cancer
|
2007
|
0.87
|
|
32
|
Towards an optimized platform for the detection, enrichment, and semi-quantitation circulating tumor cells.
|
Breast Cancer Res Treat
|
2008
|
0.86
|
|
33
|
An information-theoretic analysis of genetics, gender and age in cancer patients.
|
PLoS One
|
2008
|
0.83
|
|
34
|
Microarray gene-expression profiling to predict lymph node metastasis in penile carcinoma.
|
BJU Int
|
2008
|
0.83
|
|
35
|
Isolated isoflavones do not affect the circulating insulin-like growth factor system in men at increased colorectal cancer risk.
|
J Nutr
|
2007
|
0.82
|
|
36
|
The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype.
|
Hered Cancer Clin Pract
|
2009
|
0.82
|
|
37
|
IVS10-6T>G, an ancient ATM germline mutation linked with breast cancer.
|
Hum Mutat
|
2003
|
0.81
|
|
38
|
Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk.
|
Nutr Cancer
|
2008
|
0.79
|
|
39
|
Tools for molecular risk-stratification for clinical purposes: CLL as a prototype.
|
Eur J Hum Genet
|
2004
|
0.79
|
|
40
|
Selection of patients for hepatic surgery of colorectal cancer liver metastasis based on genomic aberrations.
|
Ann Surg Oncol
|
2013
|
0.76
|
|
41
|
No effect of red clover-derived isoflavone intervention on the insulin-like growth factor system in women at increased risk of colorectal cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
0.75
|